Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 246
- Registration Number
- NCT02544451
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 168
- Registration Number
- NCT02516410
A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2015-08-03
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 206
- Registration Number
- NCT02514473
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 34
- Registration Number
- NCT02508207
Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)
Completed
- Conditions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 75
- Registration Number
- NCT02445053
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 156
- Registration Number
- NCT02412111
A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 248
- Registration Number
- NCT02392234
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 46
- Registration Number
- NCT02390219
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 510
- Registration Number
- NCT02347657
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 40
- Registration Number
- NCT02070744
© Copyright 2024. All Rights Reserved by MedPath